A phase II trial of CI-958 in patients with hormone-refractory prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 6, 1999, Pages 511-517

  Woolley, Paul V ^a,c   Freiha, Fuad S ^b   Smith, David C ^a   Carlson, Lynn ^c   Hofacker, Janie ^a   Quinn, Nancy ^b   Grove, William ^d   Trump, Donald L ^a,e  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Laurel Highlands Cancer Program   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Chemotherapy; CI 958; Hormone resistant prostate carcinoma

Indexed keywords

LEDOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; HUMANS; INDAZOLES; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE;

EID: 0032712261     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051126     Document Type: Article

References (10)

1. 1. Donehower R, Grove W, Whitfield LR, et al (1993) Successful use of pharmacologically guided dose escalation (PGDE) in a phase 1 trial of CI-958. Proc Am Soc Clin Oncol 12: 354
2. 2. Eisenberger MA, Abrams JS (1988) Chemotherapy for prostatic carcinoma. Semin Urol 6: 303-310
3. 3. Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13: 346-353
4. 4. Parke-Davis Company (1990) Investigator's brochure, CI-958. Parke-Davis Company, Ann Arbor
5. 5. Showalter HDH, Johnson JL, Hoftiezer JM, Turner W, Werbel LM, Leopold WR, Shillis JL, Jackson RC, Elslager EF (1987) Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias. J Med Chem 30: 121-131
6. 6. Showalter HDH, Angelo MM, Berman EM, et al (1988) Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias. J Med Chem 31: 1527-1539
7. 7. Sun L, Sun PM, Turbey CM, Bachur NR (1997) Helicase blockade by CI-958, a drug for prostate cancer. Proc Am Assoc Canc Res 38: 308
8. 8. Trump DL, Freiha FS, Woolley PV, et al (1996) CI-958 Phase 2 study in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 15: 649
9. 9. Werbel LM, Elslager EF, Fry DW, Jackson RC, Leopold WR, Showalter HDH (1987) 5-Aminoanthrapyrazoles (C1-37, C1-941, C1-942): a novel class of DNA binders with broad-spectrum anticancer activity. In: Harrap KR, Connors TA (eds) New avenues in development cancer chemotherapy, vol 8. Academic Press, New York, pp 355-365
10. 10. White RJ, Durr FE (1985) Development of mitoxantrone. Invest New Drugs 3: 85-93